

23 January 2008

Sent via email

Dear Consultee/Commentator

Health Technology Appraisals

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women

and

Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Further to our letter to you of 11 December 2007, which explained that these appraisals are being returned to the Appraisal Committee after the Appeal Panel decision, we have now confirmed the date for the next Appraisal Committee meeting for these appraisals to be 6 March 2008.

As you know, the Appeal Panel has not requested more information to be submitted to the Institute and we will therefore not invite new submissions for these appraisals. However, if you have any comments or observations related to the Appeal Panel decisions which you feel need to be taken account of when the Appraisal Committee next meets to review the recommendations in the light of the Appeal Panel decision, please contact us before 21 February 2008.

We will be informing you about any new analysis which will be carried out in preparation for the meeting on 6 March very shortly.

If you have any questions about these appraisals, please contact Ms Natalie Bemrose, Technology Appraisal Project Manager (email: Natalie.bemrose@nice.org.uk or ☎ 020 7067 5930/ after 28 January 2008: 020 7045 2245).

Yours sincerely

Dr Carole Longson
Director Centre for Health Technology Evaluation